Overview

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo, Inc.
Collaborator:
AstraZeneca
Treatments:
Trastuzumab